Sigma Capital Management

Sigma Capital Management was a New York-based hedge fund and an affiliate of SAC Capital Advisors, founded by Steven A. Cohen. The firm is primarily known in the life sciences sector for its involvement in a high-profile insider trading case concerning clinical trial results for the Alzheimer's drug bapineuzumab, developed by Elan and Wyeth. Following legal proceedings and a settlement with the SEC, the firm's operations were largely curtailed as part of the broader restructuring of SAC Capital into Point72 Asset Management. While not a biotechnology company itself, its activities significantly impacted the biotech investment landscape during the early 21st century.